Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.

A noxipoint stimulating device uses light, mechanical force, and heat as a source of stimulating energy, which is configured to be applied on the Noxipoints.

Methods and compositions for treatment of pain, mood, or for the treatment of opiate withdrawal symptoms with the modulation of systemic beta-endorphin levels by the topical administration of cAMP elevating agents and/or dermal exposure to ultraviolet (UV) irradiation.

Provided herein are compositions and methods of reducing inflammation in a subject comprising administering to the subject a pharmaceutically effective amount of a mast cell desensitizing composition.

The invention relates to an NK3 agonist or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a atrial arrhythmia. The invention further relates to a composition comprising an NK3 agonist for use in the treatment of a patient suffering from a disease wherein the electrical activity of an atrial heart cell is affected.

Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.

Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.

The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.

Neurokinin 1 receptor (NK1R) agonist mediated protection of the eye is described. The protection can reduce dry eye and ocular infections, particularly in individuals with reduced NK1R activity.

Neurokinin 1 receptor (NK1R) agonist mediated protection of the eye is described. The protection can reduce dry eye and ocular infections, particularly in individuals with reduced NK1R activity.